Aytu BioPharma (LTS:0A8M) 3-Year Revenue Growth Rate : -42.90% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aytu BioPharma 3-Year Revenue Growth Rate?

Aytu BioPharma's Revenue per Share for the three months ended in Sep. 2024 was $1.82.

During the past 12 months, Aytu BioPharma's average Revenue per Share Growth Rate was -51.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -42.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was -38.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Aytu BioPharma was -29.50% per year. The lowest was -91.00% per year. And the median was -51.40% per year.

Competitive Comparison of Aytu BioPharma's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aytu BioPharma's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's 3-Year Revenue Growth Rate falls into.

Aytu BioPharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Aytu BioPharma (LTS:0A8M) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Aytu BioPharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (LTS:0A8M) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

AYTU:USA

Address

7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website

https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines